Patricia Randall, Patricia Schreck, Charles Cantor, Cheri Walker, Mark Gardner

Dec 19, 2003

Premium

Patricia Randall has become vice president, general counsel, and chief legal officer of Matritech. Prior to joining Matritech, she was vice president and general counsel of

Robotic Vision Systems

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Scan

Stricter Vaccine Standards

The US Food and Drug Administration is to announce stricter standards for emergency authorizations of SARS-CoV-2 vaccines, reports the Washington Post.

Another Trial to Ramp Up

The Associated Press reports Johnson & Johnson is starting a late-stage clinical trial of its candidate SARS-CoV-2 vaccine.

Few Billion More

Bloomberg reports the budget of Operation Warp Speed is actually $18 billion, higher than the number typically cited.

Genome Research Studies on SARS-CoV-2 Super-Spreaders, Pan-Cancer Epigenetics, More

In Genome Research this week: genomic analysis reveals role of super-spreaders in SARS-CoV-2, epigenetic drivers of cancer, and more.

Featured White Papers

COVID-19 and the SomaScan Platform

pQTL Analysis: The Latest Tool in Disease Research

Circulating Protein Biomarkers are a Promising Avenue for Predicting Patient Response to Cancer Immunotherapies

Serum Protein Signatures as a Non-Invasive Tool for Monitoring Nonalcoholic Steatohepatitis (NASH)

Oct

14

Featured Webinar

Application of ctDNA Analysis to Detect MRD and Predict Recurrence in Colorectal Cancer

Circulating tumor DNA (ctDNA) can allow clinicians and researchers to better understand which patients are at high risk of recurrence and should be offered intensified chemotherapy or selected for clinical trials.

Oct

29

Featured Webinar

How to Train Your DRAGEN for Pathology Informatics

Illumina’s BaseSpace Sequence Hub (BSSH) supports primary and secondary analysis of massively parallel sequencing data and can be applied to gene panel data that is generated as part of a clinical cancer assay performed in a pathology lab.

Menu

Patricia Randall, Patricia Schreck, Charles Cantor, Cheri Walker, Mark Gardner

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

Not ready for premium?

Breaking News

CRISPR Screen Uncovers Genes That Help Cancer Cells Evade Immune System

Pale Melanoma Susceptibility Linked to Albinism-Related Genes

Vela Diagnostics Receives Second FDA Emergency Use Authorization for SARS-CoV-2 Molecular Test

Centogene Reports 13 Percent Decline in Q2 Revenues

Metabolon Closes $72M in Debt and Equity Funding

Becton Dickinson Submits Premarket Approval Supplement to FDA for HPV Assay

The Scan

Stricter Vaccine Standards

Another Trial to Ramp Up

Few Billion More

Genome Research Studies on SARS-CoV-2 Super-Spreaders, Pan-Cancer Epigenetics, More

Featured White Papers

Application of ctDNA Analysis to Detect MRD and Predict Recurrence in Colorectal Cancer

How to Train Your DRAGEN for Pathology Informatics

Sponsorships

Menu

Get the full story with GenomeWeb Premium

Only $95 for the first 90 days*

Not ready for premium?

Sponsorships

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*